Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-18

Study Completion Date

2017-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to assess the safety and tolerability of MEDI9314 in healthy adult subjects

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

NCT02394314

Healthy Volunteers

COMPLETED PHASE1

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

NCT01544361

Healthy Subjects

COMPLETED PHASE1

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

NCT03001297

Healthy Volunteers

COMPLETED PHASE1

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

NCT02151110

Healthy Volunteer

COMPLETED PHASE1

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

NCT02388347

Healthy Adults

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase I study to assess the safety, tolerability pharmacokinetics, and immunogenicity of MEDI9314 following single dose administration to healthy subjects

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Cohort 2

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Cohort 3

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Cohort 4

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Japanese Cohort

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Cohort 5

single dose of MEDI9314 or placebo

Group Type EXPERIMENTAL

MEDI9314

Intervention Type DRUG

single dose of MEDI9314

placebo

Intervention Type DRUG

single dose of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI9314

single dose of MEDI9314

Intervention Type DRUG

placebo

single dose of placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent.
2. Age 18 through 50 years at the time of screening.
3. Female subjects must be of non-childbearing potential.
4. Nonsterilized males who are sexually active with a female partner of childbearing potential must use condom and spermicide.
5. Body mass index of 19.0 through 32.0 kg/m2 at screening.
6. No clinically significant abnormality on the basis of medical/medication history or physical examination.
7. Negative drugs of abuse (DOA).
8. Able and willing to comply with the requirements of the protocol and complete the study until the end of the safety follow up period.
9. For the Japanese Cohort, both of the subject's parents and both sets of grandparents must be Japanese.

Exclusion Criteria

1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
2. Concurrent enrollment in another clinical study involving any treatment.
3. Individuals who are legally institutionalized.
4. Receipt of \> 2 marketed or investigational biologic agents.
5. Receipt of an investigational biologic agent within 4 months or 5 half-lives prior to screening, whichever is longer.
6. Receipt of any investigational non biologic agent within 3 months or 5 half lives prior to screening, whichever is longer.
7. Use of any medication (prescription or over the counter, including herbal remedies) within 14 days or 5 half lives of Day 1, whichever is longer, unless in the opinion of the investigator and medical monitor the medication will not interfere with the study procedures or compromise subject safety.
8. Known history of allergy or reaction to any component of the investigational product formulation.
9. History of anaphylaxis following any biologic therapy.
10. Any clinically relevant abnormal findings in physical examination ECG, vital signs, and laboratory parameters.
11. Positive tuberculosis (TB) test (QuantiFERON®-TB Gold In-tube).
12. Positive hepatitis B surface antigen, hepatitis C virus antibody or HIV test at screening.
13. Receipt of live attenuated vaccines 30 days prior to the date of screening.
14. Where donation of blood or blood products was in excess of 500 mL within an 8-week period in the 3 months prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes